Stein Schalkwijk

1.0k total citations · 2 hit papers
29 papers, 555 citations indexed

About

Stein Schalkwijk is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Stein Schalkwijk has authored 29 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 6 papers in Pediatrics, Perinatology and Child Health and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Stein Schalkwijk's work include HIV/AIDS drug development and treatment (10 papers), HIV/AIDS Research and Interventions (9 papers) and Pregnancy and Medication Impact (6 papers). Stein Schalkwijk is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV/AIDS Research and Interventions (9 papers) and Pregnancy and Medication Impact (6 papers). Stein Schalkwijk collaborates with scholars based in Netherlands, United Kingdom and United States. Stein Schalkwijk's co-authors include David M. Burger, Ross J. Baldessarini, Angela Colbers, Rick Greupink, Valerio Selle, Gustavo Vázquez, Frans G. M. Rüssel, Jolien J. M. Freriksen, Mark Mirochnick and Martina Penazzato and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Clinical Infectious Diseases.

In The Last Decade

Stein Schalkwijk

26 papers receiving 543 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

2024 47 citations David J. Jackson, Michael E. Wechsler et al. New England Journal of Medicine profile →
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials

2025 17 citations Philippe Gevaert, Martin Desrosiers et al. The Lancet profile →

Peers

Countries citing papers authored by Stein Schalkwijk

Since Specialization

Citations

This map shows the geographic impact of Stein Schalkwijk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stein Schalkwijk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stein Schalkwijk more than expected).

Fields of papers citing papers by Stein Schalkwijk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stein Schalkwijk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stein Schalkwijk. The network helps show where Stein Schalkwijk may publish in the future.

Co-authorship network of co-authors of Stein Schalkwijk

This figure shows the co-authorship network connecting the top 25 collaborators of Stein Schalkwijk. A scholar is included among the top collaborators of Stein Schalkwijk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stein Schalkwijk. Stein Schalkwijk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Straight to Phase III : Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases 2026 ·Clinical Pharmacology & Therapeutics ·(unknown), Stein Schalkwijk, Isabelle Pouliquen, Aliénor Berges, (unknown), Richard Follows, Daren Austin	0
2	Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials breakdown → 2025 ·The Lancet ·Philippe Gevaert, Martin Desrosiers, Marjolein Cornet, Joaquim Mullol, Eugenio De Corso, (unknown), Jorge Máspero, Shigeharu Fujieda, Luo Zhang, Ana R. Sousa, (unknown), Angela Davis, Stein Schalkwijk, (unknown), (unknown), Richard Follows, Carol Marshall, Joseph K. Han	17
3	Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study 2025 ·Clinical Pharmacology in Drug Development ·Stein Schalkwijk, (unknown), (unknown), Samjin Choi, (unknown), Jee Sun Min, (unknown)	0
4	Pharmacokinetics and Pharmacodynamics of Twice-Yearly Depemokimab in the Randomized, Double-Blind, Placebo-Controlled Parallel Phase III ANCHOR-1/2 Trials 2025 ·Journal of Allergy and Clinical Immunology ·Martin Desrosiers, Stein Schalkwijk, (unknown), Richard Follows, Joseph K. Han	0
5	Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype breakdown → 2024 ·New England Journal of Medicine ·David J. Jackson, Michael E. Wechsler, Daniel J. Jackson, David I. Bernstein, Stephanie Korn, Paul Pfeffer, Ruchong Chen, Junpei Saito, (unknown), (unknown), Loretta Jacques, (unknown), Stein Schalkwijk, Douglas G. Smith, Peter Howarth, Ian Pavord	47
6	Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas 2021 ·Cancer Chemotherapy and Pharmacology ·Stein Schalkwijk, Li Zhou, (unknown), Lokesh Jain, Tomoko Freshwater, Karen So, (unknown), (unknown), Helen Tomkinson, Karthick Vishwanathan, Diansong Zhou	10
7	Parent and Metabolite Concentration-QT Modeling to Evaluate QT-Interval Prolongation at Savolitinib Therapeutic Doses 2021 ·The AAPS Journal ·Stein Schalkwijk, (unknown), Remy B. Verheijen, Alexander R. Harmer, (unknown)	2
8	Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens 2021 ·The Journal of Clinical Pharmacology ·(unknown), Li Zhou, Karthick Vishwanathan, Martin Wild, (unknown), Tomoko Freshwater, Lokesh Jain, Stein Schalkwijk, Helen Tomkinson, Diansong Zhou	12
9	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies 2020 ·European Journal of Clinical Pharmacology ·Roeland E. Wasmann, Elin M. Svensson, Stein Schalkwijk, Roger J. M. Brüggemann, Rob ter Heine	3
10	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study 2018 ·Targeted Oncology ·(unknown), Rutger H.T. Koornstra, Johanna H. M. Driessen, Bas van Vlijmen, Sander Croes, Stein Schalkwijk, Angela Colbers, Winald R. Gerritsen, David M. Burger, Frank de Vries, Nielka P. van Erp	4
11	Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps 2018 ·Clinical Pharmacokinetics ·(unknown), Rob ter Heine, Rick Greupink, Stein Schalkwijk, Antonius E. van Herwaarden, Angela Colbers, David M. Burger	39
12	Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma 2018 ·Journal of Chromatography B ·(unknown), (unknown), Stein Schalkwijk, Nielka P. van Erp, David M. Burger	33
13	Efavirenz Pharmacokinetics during Pregnancy and Infant Washout 2018 ·Antiviral Therapy ·Régis Kreitchmann, Stein Schalkwijk, Brookie M. Best, Jiajia Wang, Angela Colbers, Alice Stek, David E. Shapiro, Tim R. Cressey, Mark Mirochnick, David M. Burger	16
14	Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling 2017 ·Clinical Pharmacokinetics ·Stein Schalkwijk, (unknown), Jolien J. M. Freriksen, Angela Colbers, David M. Burger, Rick Greupink, Frans G. M. Rüssel	48
15	Etravirine Pharmacokinetics in HIV-Infected Pregnant Women 2016 ·Frontiers in Pharmacology ·(unknown), Stein Schalkwijk, Brookie M. Best, Angela Colbers, Jiajia Wang, Edmund V. Capparelli, José Moltó, Alice Stek, Graham P. Taylor, Elizabeth Smith, Carmen Hidalgo Tenorio, Nahida Chakhtoura, (unknown), Courtney V. Fletcher, Mark Mirochnick, David M. Burger	15
16	Lidocaine-Associated Cardiac Events in Newborns with Seizures: Incidence, Symptoms and Contributing Factors 2015 ·Neonatology ·Lauren C. Weeke, Stein Schalkwijk, Mona C. Toet, Linda G.M. van Rooij, Linda S. de Vries, Marcel P. H. van den Broek	19
17	Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model 2015 ·Journal of Antimicrobial Chemotherapy ·Stein Schalkwijk, Rick Greupink, Angela Colbers, Alfons C. Wouterse, Viviènne Verweij, J. van Drongelen, Marga Teulen, (unknown), David M. Burger, Frans G. M. Rüssel	29
18	Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women 2015 ·Clinical Infectious Diseases ·(unknown), Brookie M. Best, Stein Schalkwijk, Jiajia Wang, Alice Stek, Carmen Hidalgo Tenorio, David Hawkins, Graham P. Taylor, Régis Kreitchmann, Sandra Burchett, Annette Haberl, Kabamba Kabeya, (unknown), Elizabeth Smith, Edmund V. Capparelli, David M. Burger, Mark Mirochnick	13
19	Declining efficacy in controlled trials of antidepressants: effects of placebo dropout 2014 ·The International Journal of Neuropsychopharmacology ·Stein Schalkwijk, Juan Undurraga, Leonardo Tondo, Ross J. Baldessarini	24
20	Re-analysis of the earliest controlled trials of imipramine 2012 ·Journal of Affective Disorders ·Juan Undurraga, Leonardo Tondo, Stein Schalkwijk, Eduard Vieta, Ross J. Baldessarini	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact